Literature DB >> 32128647

A Comparative Study of 22G versus 19G Needles for EUS-Guided Biopsies for Parenchymal Liver Disease: Are Thinner Needles Better?

Harsh K Patel1, Romil Saxena2, Natalia Rush2, Suchi K Patel3, Chandra S Dasari4, Wadad Mneimneh5, Ariel Quickery2, Mahmoud A Rahal2, Lindsey Temnykh2, John DeWitt2, Mohammad Al-Haddad6.   

Abstract

BACKGROUND AND AIMS: Data on comparative efficacy of various available endoscopic ultrasound-guided liver biopsy (EUS-LB) needles are limited. We sought to compare the performance of a novel Franseen-tip 22G fine-needle biopsy (FNB) device to that of 19G needle platforms for liver parenchyma.
METHODS: Consecutive patients referred for EUS and suspected to have hepatic parenchymal disease underwent EUS-LB using different EUS needles and were included in this retrospective study. Two blinded expert liver pathologists independently reviewed and reported on: total number of tissue fragments, length of longest fragment, number of complete and incomplete portal tracts (CPT and IPT), and specimen adequacy.
RESULTS: A 22G Franseen-tip needle (A) was used in 30 patients; 19G Tru-Cut needle (B) in 50 patients; 19G reverse beveled non-Tru-Cut needle (C) in 27 patients; and a 19G flexible non-Tru-Cut needle (D) in 28 patients. In the order of needles, A, B, C and D,  > 10 tissue fragments were obtained in 100%, 6%, 82%, and 96% samples, the mean number of CPTs was 6.9; 3.0; 7.3; and 16.9, length of longest fragment was 3.8, 4. 7, 3.9, and 8.4 mm, and specimen adequacy was 66.7%, 46%, 82.1%, and 81.5%, respectively. A positive correlation was obtained between number of CPTs and length of longest fragment in samples accrued by 19G needles.
CONCLUSION: EUS-LB specimens using 22G Franseen-tip needle appear highly fragmented, leading to inferior specimen adequacy compared to 19G non-Tru-Cut needles. We also report on using length of longest fragment as an additional criterion for specimen adequacy as it positively correlates with number of CPTs standard.

Entities:  

Keywords:  22G; Adequacy; Endoscopic ultrasound; Fine-needle aspiration (FNA); Fine-needle biopsy (FNB); Liver biopsy

Year:  2020        PMID: 32128647     DOI: 10.1007/s10620-020-06165-x

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

Review 1.  Liver biopsy.

Authors:  A A Bravo; S G Sheth; S Chopra
Journal:  N Engl J Med       Date:  2001-02-15       Impact factor: 91.245

2.  Comparison of EUS-guided versus percutaneous and transjugular approaches for the performance of liver biopsies.

Authors:  Asim Shuja; Ahmad Alkhasawneh; Andre Fialho; Andrea Fialho; Amal Shukri; Ciel Harris; Carmen Smotherman; Miguel Malespin; Silvio W de Melo
Journal:  Dig Liver Dis       Date:  2019-01-22       Impact factor: 4.088

3.  Efficacy and safety of EUS-guided liver biopsy: a systematic review and meta-analysis.

Authors:  Babu P Mohan; Mohammed Shakhatreh; Rajat Garg; Suresh Ponnada; Douglas G Adler
Journal:  Gastrointest Endosc       Date:  2018-10-31       Impact factor: 9.427

4.  One hundred thirteen consecutive transgastric liver biopsies for hepatic parenchymal diseases: a single-institution study.

Authors:  Yukihiro Nakanishi; Wadad S Mneimneh; Michael Sey; Mohammad Al-Haddad; John M DeWitt; Romil Saxena
Journal:  Am J Surg Pathol       Date:  2015-07       Impact factor: 6.394

5.  [Sonographically assisted liver biopsy--replacement for blind needle biopsy?].

Authors:  L Greiner; F H Franken
Journal:  Dtsch Med Wochenschr       Date:  1983-03-11       Impact factor: 0.628

6.  Initial experience with EUS-guided Tru-cut biopsy of benign liver disease.

Authors:  John Dewitt; Kathleen McGreevy; Oscar Cummings; Stuart Sherman; Julia K Leblanc; Lee McHenry; Mohammad Al-Haddad; Naga Chalasani
Journal:  Gastrointest Endosc       Date:  2009-03       Impact factor: 9.427

7.  Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease.

Authors:  Ferga C Gleeson; Amy C Clayton; Lizhi Zhang; Jonathan E Clain; Gregory J Gores; Elizabeth Rajan; Tom C Smyrk; Mark D Topazian; Kenneth K Wang; Maurits J Wiersema; Michael J Levy
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-26       Impact factor: 11.382

8.  [Ultrasound-guided puncture-biopsy of the liver could replace blind puncture-biopsy in diffuse hepatopathies. Retrospective study of 1293 patients].

Authors:  J P Joly; S Khouani; C Decrombecque; A Razafimahaleo; H Sevestre; J P Capron
Journal:  Gastroenterol Clin Biol       Date:  1995 Aug-Sep

9.  EUS-guided liver biopsy provides diagnostic samples comparable with those via the percutaneous or transjugular route.

Authors:  Jonh J Pineda; David L Diehl; Chuan L Miao; Amitpal S Johal; Harshit S Khara; Ashok Bhanushali; Eric Z Chen
Journal:  Gastrointest Endosc       Date:  2015-08-22       Impact factor: 9.427

Review 10.  Endoscopic ultrasound-guided liver biopsy.

Authors:  Parth J Parekh; Raj Majithia; David L Diehl; Todd H Baron
Journal:  Endosc Ultrasound       Date:  2015 Apr-Jun       Impact factor: 5.628

View more
  4 in total

Review 1.  A State-of-the-Art Review on the Evolving Utility of Endoscopic Ultrasound in Liver Diseases Diagnosis.

Authors:  Wisam Sbeit; Anas Kadah; Mahmud Mahamid; Rinaldo Pellicano; Amir Mari; Tawfik Khoury
Journal:  Diagnostics (Basel)       Date:  2020-07-23

2.  Endoscopic ultrasound-guided tissue acquisition for splenic lesions: A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Xiao Pan; Shu Huang; Peiling Gan; Lei Shi; Huifang Xia; Xinyi Zeng; Han Zhang; Muhan Lü; Xian Zhou; Xiaowei Tang
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

3.  Role of endoscopic ultrasound in the field of hepatology: Recent advances and future trends.

Authors:  Jahnvi Dhar; Jayanta Samanta
Journal:  World J Hepatol       Date:  2021-11-27

Review 4.  Update on endoscopic ultrasound-guided liver biopsy.

Authors:  Shiva Rangwani; Devarshi R Ardeshna; Khalid Mumtaz; Sean G Kelly; Samuel Y Han; Somashekar G Krishna
Journal:  World J Gastroenterol       Date:  2022-07-28       Impact factor: 5.374

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.